This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less riskMarket Watch • 02/12/24
GSK's RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased RiskBusiness Wire • 02/06/24
The Cutting Edge: 3 Stocks to Buy for the Next Generation of Biotech BreakthroughsInvestorPlace • 01/25/24
Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen's Cell-Free DNA Production TechnologyBusiness Wire • 01/24/24